More specifically, a posthoc analysis of two trials (PARADIGM-HF and PARAGON-HF) found that patients at the highest end of the ejection fraction range had lower overall mortality but higher proportions of noncardiovascular deaths and had not benefited from sacubitril/valsartan compared with angiotensin receptor blockers or angiotensin converting enzyme (ACE) inhibitors alone. The gene discussed is ACE; the disease is hydrops fetalis.